Cellectar (CLRB) news
Recent news
StemPoint Capital LP reports 9.9% passive stake in Cellectar Biosciences Inc as of June 30 - SEC filing
AInvest Wire · Aug 14, 2026Cellectar Biosciences files for $300M mixed securities shelf
Cellectar Biosciences files for $300M mixed securities shelf Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has recently filed a prospectus for a $300 million mixed securities shelf, highlighting its commitment to the discovery, development, and commercialization of…
AInvest Wire · May 24, 2024ImportantCellectar BioSciences surges 52% premarket after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom’s macroglobulinemia
Cellectar BioSciences surges 52% premarket after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom’s macroglobulinemia Cellectar BioSciences, a late-stage clinical biopharmaceutical company, has announced positive topline data…
AInvest Wire · Jan 8, 2024ImportantCellectar Biosciences Shares Rise 10% After Being Granted Four Patents
AInvest Wire · Oct 2, 2023ImportantCellectar Biosciences gets EMA prime designation for Iopofosine
AInvest Wire · Sep 18, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.